CURRICULUM VITAE Dr. Maria Todaro

Personal data

Date of birth: August 27, 1981
Place of birth: Torino (TO), Italy

Citizenship: Italian

Work address: Laboratory of the Division of Hematology (Director: Prof. Mario Boccadoro), Via Genova 3, 10126 Torino, Italy;

Phone: +39-011-6334254, 3470818936 Fax: +39-011-6336887.

E-mail:

Education

Jul 2016 Ph.D in Molecular Medicine - University of Torino, Italy

Jul 2010 Master of Science in Medical Biotechnologies, University of Torino, Italy

Sept 2007 HealthcareBiotechnology Bachelor Degree, University of Todaro, Italy

Research Experience

2016-present: University of Turin, Laboratory of the Division of Hematology (A.U.O. Città della Salute e della Scienza).Postdoctoral Researcher

2014-2015:Weill Cornell Medical College, New York City (NY). Dept. of Pathology & Laboratory Medicine Post-Doctoral Research Associate.

2010-2014:University of Turin, Center for Experimental Research and Medical Studies. Inteship

2003-2008:University of Turin, O.I.R.M. Sant’Anna Hospital, Pharmacy Laboratory. Visiting student

Technical skills and competences

Cellular Biology: Culture of adhesion and suspension cell lines; DNA Transfection, Transduction and Transformation; production of Lenti- and Retro- virus; shRNA techniques; Flow Cytometry (Cell Cycle analysis, Annexin V, Propidium Iodide, TMRM); Ficoll; Protein (whole cell, histones and cell fractionation nucleus/cytoplasm,purification), DNA and RNA extraction (cells/tissues); Proliferation and Cell Death assay (Cell Titer Glow, Cell Titer Blue, MTT); Colony forming assay (2D and 3D); Primary Cells culture.

Molecular Biology: DNA cloning techniques (Classic, TA Cloning, Gateway System); PCR; RT-PCR; DNA sequencing analysis; Site direct mutagenesis; DNA isolation from bacteria; Western Blot; Immunoprecipitation; Pull Down; Reporter Assay; ELISA.

In vivo skills: Autopsy, organs collection, biobanking.

Lab Management: Supervise technical staff members in a productive and professional manners; Recruited and conducted orientations and training to new staffs (including students); Analyzed toxicological information and reported any safety hazardous to management.

Publications

1. Agnelli L, Mereu E, Pellegrino E, Limongi T, Kwee I, Bergaggio E, Ponzoni M, Zamò A, Iqbal J, Piccaluga PP, Neri A, Chan WC, Pileri S, Bertoni F, Inghirami G, Piva R; European T-Cell Lymphoma Study Group (Todaro M et al). Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma. Blood 2012,

120:1274-81. IF 10,452

2. Tabbó F, Barreca A, Piva R, Inghirami G; The European T-Cell Lymphoma Study Group (Todaro M et al). ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma. Front Oncol. 2012;2:41. Review. IF 4,59

3. Laimer D, Dolznig H, Kollmann K, Vesely PW, Schlederer M, Merkel O, Schiefer AI, Hassler MR, Heider S, Amenitsch L, Thallinger C, Staber PB, Simonitsch-Klupp I, Artaker M, Lagger S, Turner SD, Pileri S, Piccaluga PP, Valent P, Messana K, Landra I, Weichhart T, Knapp S, Shehata M, Todaro M, Sexl V, Höfler G, Piva R, Medico E, Ruggeri BA, Cheng M, Eferl R, Egger G, Penninger JM, Jaeger U, Moriggl R, Inghirami G, Kenner L.PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas.Nat Med. 2012;18:1699-704. IF 27,363

4. Voena C, Di Giacomo F, Panizza E, D'Amico L, Boccalatte FE, Pellegrino E, Todaro M, Recupero D, Tabbò F, Ambrogio C, Martinengo C, Bonello L, Pulito R, Hamm J, Chiarle R, Cheng M, Ruggeri B, Medico E, Inghirami G.The EGFR family members sustain the neoplastic phenotype of ALK+ lung adenocarcinoma via EGR1. Oncogenesis. 2013 Apr 8;2:e43. IF 5,29

5. Tabbò F, Ponzoni M, Rabadan R, Bertoni F, Inghirami G; European T-cell Lymphoma Study Group (Todaro M et al). Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis: alternative drivers in anaplastic large cell lymphoma. Curr Opin Hematol. 2013;20:374-81. Review. IF 3,97

6. Boi M, Rinaldi A, Kwee I, Bonetti P, Todaro M, Tabbo’ F, Piva R, Rancoita PMV, Matolcsy A, Timar B, Tousseyn T, Rodriguez-Pinilla SC, Piris MA, Beà S, Campo E, Bhagat G, Swerdlow SH, Rosenwald A, Ponzoni M, Young KH, Piccaluga PP, Tzankov A, Dummer R, Pileri S, Zucca E, Inghirami G, Bertoni F. BLIMP1/PRDM1 is commonly inactivated in Anaplastic Large T-cell Lymphoma. Blood 2013;122:2683-93. IF 10,452

7. Abate F*, Todaro M*, van der Krogt JA, Boi M, Landra I, Machiorlatti R, Tabbò F, Messana K, Abele C, Barreca A, Novero D, Gaudiano M, Aliberti S, Di Giacomo F, Tousseyn T, Lasorsa E, Crescenzo R, Bessone L, Ficarra E, Acquaviva A, Rinaldi A, Ponzoni M, Longo DL, Aime S, Cheng M, Ruggeri B, Piccaluga PP, Pileri S, Tiacci E, Falini B, Pera-Gresely B, Cerchietti L, Iqbal J, Chan WC, Shultz LD, Kwee I, Piva R, Wlodarska I, Rabadan R, Bertoni F, Inghirami G; European T-cell Lymphoma Study Group. A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation. Leukemia. 2015 Jun;29(6):1390-401. IF 10,431

8. Crescenzo R, Abate F, Lasorsa E, Tabbo' F, Gaudiano M, Chiesa N, Di Giacomo F, Spaccarotella E, Barbarossa L, Ercole E, Todaro M, Boi M, Acquaviva A, Ficarra E, Novero D, Rinaldi A, Tousseyn T, Rosenwald A, Kenner L, Cerroni L, Tzankov A, Ponzoni M, Paulli M, Weisenburger D, Chan WC, Iqbal J, Piris MA, Zamo' A, Ciardullo C, Rossi D, Gaidano G, Pileri S, Tiacci E, Falini B, Shultz LD, Mevellec L, Vialard JE, Piva R, Bertoni F, Rabadan R, Inghirami G; European T-Cell Lymphoma Study Group, T-Cell Project: Prospective Collection of Data in Patients with Peripheral T-Cell Lymphoma and the AIRC 5xMille Consortium “Genetics-Driven Targeted Management of Lymphoid Malignancies”. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell. 2015 Apr 13;27(4):516-32. IF 23,523

  1. Pizzi M, Gaudiano M, Todaro M, Inghirami G.Anaplastic lymphoma kinase: activating mechanisms and signaling pathways. Front Biosci (Schol Ed). 2015 Jun 1;7:283-305. Review.

IF 3,52

10.Irene Scarfò, Elisa Pellegrino, Elisabetta Mereu, Ivo Kwee, Luca Agnelli, Elisa Bergaggio, Giulia Garaffo, Nicoletta Vitale, Manuel Caputo, Rodolfo Machiorlatti, Paola Circosta, Francesco Abate, Antonella Barreca, Domenico Novero, Susan Mathew, Andrea Rinaldi, Enrico Tiacci, Sara Serra, Silvia Deaglio, Antonino Neri, Brunangelo Falini, Raul Rabadan, Francesco Bertoni, Giorgio Inghirami, Roberto Piva, the European T-Cell Lymphoma Study Group, (Todaro M et al ) Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts . Blood 2016 127:221-232. IF 10,452

11. Francesco Guerrera, Fabrizio Tabbò, Luca Bessone, Francesca Maletta, Marcello Gaudiano, Elisabetta Ercole,Laura Annaratone, Maria Todaro,Monica Boita, Pier Luigi Filosso, Paolo Solidoro, Luisa Delsedime, Alberto Oliaro, Anna Sapino, Enrico Ruffini, and Giorgio Inghirami. The Influence of Tissue Ischemia Time on RNA Integrity and Patient-Derived Xenografts (PDX) Engraftment Rate in a Non-Small Cell Lung Cancer (NSCLC) Biobank. PLoS One 2016 11(1): e0145100. IF 4,17

12.Michela Boi*, Maria Todaro*, Valentina Vurchio, Shao Ning Yang, John Moon, Ivo Kwee, Andrea Rinaldi, Heng Pan, Ramona Crescenzo, Mangeng Cheng, Leandro Cerchietti, Olivier Elemento, Maria E Riveiro, Esteban Cvitkovic, Francesco Bertoni, Giorgio Inghirami, Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.Oncotarget 2016(Accepted for publication) IF 6,359.